Chris Benton, MD, provides an overview of first-line treatment options for patients with lower-risk myelodysplastic syndromes (LR-MDS).
Chris Benton, MD
Advertisement
Chris Benton, MD, is a hematologist-oncologist at Rocky Mountain Cancer Centers.
Articles by Chris Benton, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
